US6586458B1
(en)
|
1996-08-16 |
2003-07-01 |
Pozen Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US8022095B2
(en)
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US6077539A
(en)
*
|
1996-11-12 |
2000-06-20 |
Pozen, Inc. |
Treatment of migraine headache
|
GB9814215D0
(en)
*
|
1998-07-01 |
1998-09-02 |
Norton Healthcare Ltd |
Anti-inflammatory pharmaceutical formulations
|
ATE284691T1
(en)
|
1998-11-02 |
2005-01-15 |
Merck & Co Inc |
COMPOSITIONS OF A 5HT1B/1D AGONIST AND A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF MIGRAINE
|
SA99191255B1
(en)
*
|
1998-11-30 |
2006-11-25 |
جي دي سيرل اند كو |
celecoxib compounds
|
AU3596500A
(en)
*
|
1999-02-19 |
2000-09-04 |
Pozen, Inc. |
Formulation of 5-ht agonists with cox-2 inhibitors
|
AU2001285334A1
(en)
|
2000-08-29 |
2002-03-13 |
Peter Van Patten |
Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
|
US6440983B1
(en)
*
|
2000-12-21 |
2002-08-27 |
Mary Theresa Frank-Kollman |
Compositions and methods for relieving headache symptoms in aspirin-sensitive headache sufferers
|
US8206741B2
(en)
|
2001-06-01 |
2012-06-26 |
Pozen Inc. |
Pharmaceutical compositions for the coordinated delivery of NSAIDs
|
US6685951B2
(en)
|
2001-07-05 |
2004-02-03 |
R. T. Alamo Ventures I, Inc. |
Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
|
US20030198669A1
(en)
*
|
2001-07-05 |
2003-10-23 |
R.T. Alamo Ventures I, Llc |
Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
|
US20030017175A1
(en)
*
|
2001-07-05 |
2003-01-23 |
R.T. Alamo Ventures I, Inc. |
Sublingual administration of dihydroergotamine for the treatment of migraine
|
US7838026B2
(en)
|
2001-09-28 |
2010-11-23 |
Mcneil-Ppc, Inc. |
Burst-release polymer composition and dosage forms comprising the same
|
BR0212951A
(en)
|
2001-09-28 |
2004-10-26 |
Mcneil Ppc Inc |
Composite Dosage Forms
|
US7122143B2
(en)
|
2001-09-28 |
2006-10-17 |
Mcneil-Ppc, Inc. |
Methods for manufacturing dosage forms
|
JP2005533830A
(en)
*
|
2002-07-09 |
2005-11-10 |
ビー.エム.アール.エイ. コーポレイション ベスローテン フェンノートシャップ |
Thromboxane A2 receptor antagonist and COX-2 inhibitor drug combination
|
US7807197B2
(en)
|
2002-09-28 |
2010-10-05 |
Mcneil-Ppc, Inc. |
Composite dosage forms having an inlaid portion
|
JP4616009B2
(en)
*
|
2002-12-26 |
2011-01-19 |
ポーゼン インコーポレイテッド |
Multi-layer dosage form containing NSAIDs and triptan
|
US20080213363A1
(en)
*
|
2003-01-23 |
2008-09-04 |
Singh Nikhilesh N |
Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
|
US20100297252A1
(en)
|
2003-03-03 |
2010-11-25 |
Elan Pharma International Ltd. |
Nanoparticulate meloxicam formulations
|
US8512727B2
(en)
*
|
2003-03-03 |
2013-08-20 |
Alkermes Pharma Ireland Limited |
Nanoparticulate meloxicam formulations
|
US20040192781A1
(en)
*
|
2003-03-31 |
2004-09-30 |
Haley Eugene T. |
Method of administration for metoclopramide and pharmaceutical formulation therefor
|
US20050137265A1
(en)
*
|
2003-03-31 |
2005-06-23 |
Haley Eugene T. |
Rapidly dissolving metoclopramide solid oral dosage and method thereof
|
WO2004110492A2
(en)
*
|
2003-06-06 |
2004-12-23 |
Glaxo Group Limited |
Composition comprising triptans and nsaids
|
WO2005016334A1
(en)
*
|
2003-08-07 |
2005-02-24 |
B.M.R.A. Corporation B.V. |
Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxigenase-1
|
JP2007505136A
(en)
*
|
2003-09-10 |
2007-03-08 |
マツプ・フアーマシユーテイカルズ・インコーポレーテツド |
Aerosol formulation for delivering dihydroergotamine to systemic circulation by pulmonary inhalation
|
US7879354B2
(en)
|
2004-01-13 |
2011-02-01 |
Mcneil-Ppc, Inc. |
Rapidly disintegrating gelatinous coated tablets
|
US8067029B2
(en)
|
2004-01-13 |
2011-11-29 |
Mcneil-Ppc, Inc. |
Rapidly disintegrating gelatinous coated tablets
|
US20070065486A1
(en)
*
|
2004-05-21 |
2007-03-22 |
Migco Limited |
Migraine remedy
|
US8216610B2
(en)
*
|
2004-05-28 |
2012-07-10 |
Imaginot Pty Ltd. |
Oral paracetamol formulations
|
US20050282879A1
(en)
*
|
2004-06-17 |
2005-12-22 |
Foad Salehani |
Methods and composition for treatment of migraine and symptoms thereof
|
US20060178349A1
(en)
*
|
2005-01-24 |
2006-08-10 |
Pozen Inc. |
Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
|
US8673352B2
(en)
|
2005-04-15 |
2014-03-18 |
Mcneil-Ppc, Inc. |
Modified release dosage form
|
WO2007059591A1
(en)
|
2005-11-28 |
2007-05-31 |
Imaginot Pty Ltd |
Oral therapeutic compound delivery system
|
US9265732B2
(en)
*
|
2006-03-06 |
2016-02-23 |
Pozen Inc. |
Dosage forms for administering combinations of drugs
|
CA2644435C
(en)
*
|
2006-03-06 |
2015-04-07 |
Pozen Inc. |
Dosage forms for administering combinations of drugs
|
US8685452B2
(en)
*
|
2006-06-16 |
2014-04-01 |
Lek Pharmaceuticals D.D. |
Pharmaceutical composition
|
US8128460B2
(en)
*
|
2006-09-14 |
2012-03-06 |
The Material Works, Ltd. |
Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
|
ITMI20062254A1
(en)
*
|
2006-11-24 |
2008-05-25 |
Acraf |
USE OF A METHOXY-ALCANOIC ACID OF THE INZOL TO PREPARE A PHARMACEUTICAL COMPOSITION
|
ES2538082T3
(en)
|
2007-02-11 |
2015-06-17 |
Map Pharmaceuticals Inc |
Therapeutic administration method of DHE to allow rapid migraine relief while minimizing the side effects profile
|
PE20090185A1
(en)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR
|
TR200708925A1
(en)
*
|
2007-12-26 |
2009-07-21 |
Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ |
Combinations of flurbiprofen and muscle relaxants for controlled release
|
CA2905541C
(en)
|
2008-01-09 |
2020-02-11 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
US20090186086A1
(en)
*
|
2008-01-17 |
2009-07-23 |
Par Pharmaceutical, Inc. |
Solid multilayer oral dosage forms
|
ES2817504T3
(en)
*
|
2008-01-25 |
2021-04-07 |
Laboratoires Majorelle |
Oral Drug Combinations Bound by an Envelope
|
EP2344139A1
(en)
|
2008-09-09 |
2011-07-20 |
AstraZeneca AB |
Method for delivering a pharmaceutical composition to patient in need thereof
|
US8551454B2
(en)
*
|
2009-03-13 |
2013-10-08 |
Luitpold Pharmaceuticals, Inc. |
Device for intranasal administration
|
SG176724A1
(en)
*
|
2009-06-25 |
2012-01-30 |
Astrazeneca Ab |
Method for treating a patient at risk for developing an nsaid-associated ulcer
|
JP2012531430A
(en)
*
|
2009-06-25 |
2012-12-10 |
ポーゼン インコーポレイテッド |
Methods for treating patients in need of aspirin therapy
|
WO2010151804A1
(en)
*
|
2009-06-26 |
2010-12-29 |
Map Pharmaceuticals, Inc. |
Administration of dihydroergotamine mesylate particles using a metered dose inhaler
|
CA2767576C
(en)
|
2009-07-08 |
2020-03-10 |
Charleston Laboratories Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
EP2797600A4
(en)
|
2011-12-28 |
2015-09-16 |
Pozen Inc |
Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
|
EP2702875A1
(en)
*
|
2012-08-31 |
2014-03-05 |
Südzucker Aktiengesellschaft Mannheim/Ochsenfurt |
Coated comestibles with a chocolate core and processes for their preparation
|
PL3060203T3
(en)
*
|
2013-10-23 |
2018-01-31 |
Bayer Healthcare Llc |
Effervescent tablet containing high level of aspirin
|
EA032777B1
(en)
|
2013-12-24 |
2019-07-31 |
Вирджиния Коммонвелт Юниверсити |
Method of preventing or treating kidney failure
|
US20150290174A1
(en)
*
|
2014-04-11 |
2015-10-15 |
Resuscitate MOE LLC |
Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine
|
WO2016089893A1
(en)
*
|
2014-12-01 |
2016-06-09 |
Achelios Therapeutics Inc. |
Methods and compositions for treating migraine and conditions associated with pain
|
US11045549B2
(en)
|
2015-02-10 |
2021-06-29 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10933136B2
(en)
|
2015-02-10 |
2021-03-02 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11738085B2
(en)
|
2015-02-10 |
2023-08-29 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10729774B1
(en)
|
2015-02-10 |
2020-08-04 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11607456B2
(en)
|
2015-02-10 |
2023-03-21 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10722583B2
(en)
|
2015-02-10 |
2020-07-28 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11110173B2
(en)
|
2015-02-10 |
2021-09-07 |
Axsome Therapeutics, Inc |
Pharmaceutical compositions comprising meloxicam
|
US10537642B1
(en)
|
2015-02-10 |
2020-01-21 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11602563B2
(en)
|
2015-02-10 |
2023-03-14 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10758618B2
(en)
|
2015-02-10 |
2020-09-01 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10799588B2
(en)
|
2015-02-10 |
2020-10-13 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10695429B2
(en)
|
2015-02-10 |
2020-06-30 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10729773B2
(en)
|
2015-02-10 |
2020-08-04 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10780165B2
(en)
|
2015-02-10 |
2020-09-22 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10653777B2
(en)
|
2015-02-10 |
2020-05-19 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10058614B2
(en)
|
2015-02-10 |
2018-08-28 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10695430B2
(en)
|
2015-02-10 |
2020-06-30 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10702602B2
(en)
|
2015-02-10 |
2020-07-07 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10512692B2
(en)
|
2015-02-10 |
2019-12-24 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10933137B2
(en)
|
2015-02-10 |
2021-03-02 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11013806B2
(en)
|
2015-02-10 |
2021-05-25 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10517950B1
(en)
|
2015-02-10 |
2019-12-31 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10532101B1
(en)
|
2015-02-10 |
2020-01-14 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11013805B2
(en)
|
2015-02-10 |
2021-05-25 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10821181B2
(en)
|
2015-02-10 |
2020-11-03 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10780166B2
(en)
|
2015-02-10 |
2020-09-22 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
EP3973957A1
(en)
|
2015-03-26 |
2022-03-30 |
Sen-Jam Pharmaceutical LLC |
Methods and compositions to inhibit symptoms associated with veisalgia
|
WO2017152130A1
(en)
|
2016-03-04 |
2017-09-08 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions
|
US10583088B2
(en)
|
2017-01-04 |
2020-03-10 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10471014B2
(en)
|
2017-01-04 |
2019-11-12 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10940153B2
(en)
|
2017-01-04 |
2021-03-09 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10583144B2
(en)
|
2017-01-04 |
2020-03-10 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10561664B1
(en)
|
2017-01-04 |
2020-02-18 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11433078B2
(en)
|
2017-01-04 |
2022-09-06 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11801250B2
(en)
|
2017-01-04 |
2023-10-31 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11471465B2
(en)
|
2017-01-04 |
2022-10-18 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10894053B2
(en)
|
2017-01-04 |
2021-01-19 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11266657B2
(en)
|
2017-01-04 |
2022-03-08 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11207327B2
(en)
|
2017-01-04 |
2021-12-28 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10821182B2
(en)
|
2017-06-29 |
2020-11-03 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10729697B2
(en)
|
2017-01-04 |
2020-08-04 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11617755B2
(en)
|
2017-01-04 |
2023-04-04 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10729696B2
(en)
|
2017-01-04 |
2020-08-04 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11806354B2
(en)
|
2017-01-04 |
2023-11-07 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11433079B2
(en)
|
2017-01-04 |
2022-09-06 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
RS61346B1
(en)
|
2017-01-04 |
2021-02-26 |
Axsome Therapeutics Inc |
Pharmaceutical compositions comprising meloxicam and rizatriptan
|
US10905693B2
(en)
|
2017-01-04 |
2021-02-02 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10512693B2
(en)
|
2017-06-29 |
2019-12-24 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10758617B2
(en)
|
2017-06-29 |
2020-09-01 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10688185B2
(en)
|
2017-06-29 |
2020-06-23 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11185550B2
(en)
|
2017-06-29 |
2021-11-30 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11759522B2
(en)
|
2017-06-29 |
2023-09-19 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11617756B2
(en)
|
2017-06-29 |
2023-04-04 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10987358B2
(en)
|
2017-06-29 |
2021-04-27 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11219626B2
(en)
|
2017-06-29 |
2022-01-11 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11617791B2
(en)
|
2017-06-29 |
2023-04-04 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10688102B2
(en)
|
2017-06-29 |
2020-06-23 |
Axsome Therapeutics, Inc. |
Combination treatment for migraine and other pain
|
US11510927B2
(en)
|
2017-06-29 |
2022-11-29 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US10918722B2
(en)
|
2017-06-29 |
2021-02-16 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising meloxicam
|
US11865117B2
(en)
|
2017-06-29 |
2024-01-09 |
Axsome Therapeutics, Inc |
Pharmaceutical compositions comprising meloxicam
|
CN111295198A
(en)
*
|
2017-11-01 |
2020-06-16 |
表飞鸣制药株式会社 |
Preventive or therapeutic agent for small intestine injury induced by specific NSAIDs and PPI
|
JP2020103185A
(en)
*
|
2018-12-27 |
2020-07-09 |
花王株式会社 |
Effervescent oral tablets contained in sealed container
|
US11779541B2
(en)
*
|
2019-03-26 |
2023-10-10 |
Johnson & Johnson Consumer Inc. |
Immediate release dosage form
|